1. TFAP2A knockdown inhibits tumor growth in vivo.
TFAP2A knockdown inhibits tumor growth in vivo. The DOTAP-cholesterol nanoparticle-encapsulated TFAP2A siRNA (si-TFAP2A) and nonspecific scramble siRNA (si-NS) were injected into the tumors of mice. Day 0 corresponds to 2 weeks after inoculation of CNE2 cells and the first treatment when tumor volume was 150 to 160 mm3. Tumor diameters were measured at a regular interval of 4 days for up to 27 days with a digital caliper, and the tumor volume was calculated (A). The xenografts were harvested at 27 days after treatment. The pictures of the tumors were taken (B), and the weights of the tumors were analyzed (C). The expression levels of TFAP2A, HIF-1α, VEGF, and PEDF proteins in tumor tissues were detected by immunohistochemical staining (D). The CD34 expression was also examined by immunohistochemistry and the MVD was quantitatively analyzed (E). *, P < 0.05, significant differences between TFAP2A siRNA (si-TFAP2A) groups and the nonspecific scramble siRNA (si-NS) groups. n = 7 mice/group. Magnification, ×400.
Dingbo Shi et al. Cancer Prev Res 2014;7:
©2014 by American Association for Cancer Research